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• The key mechanisms associated with irreversible 
hemorrhagic shock have no so far been elucidated. The 
involvement of mast cells in this phenomenon, however, has 
already been studied. On the other hand, fl-endorphine and 
various opiates, or any stressful stimuli mediated by endoge- 
nous opiates, cause mast cell degranulation and histamine 
release, as the study of the related literature shows. 
Hemorrhagic shock is one such stressful stimulus that leads 
to an increase in the plasma levels of endogenous opioids, 
especially fl-endorphine. During hemorrhagic shock, there- 
fore, mast cells can be activated by an elevation of the f3- 
endorphine level; and the degranulatedproducts of mast cells, 
histamine in particular, may contribute to the progress of 
hemorrhagic shock to the irreversible state. 
The investigation of the effect of hemorrhage on mast cell 
degranulation has shown that there is a positive correlation 
between the two phenomena. In addition, it has been estab- 
lished that the administration ofvasoactive intestinalpeptide 
(VIP) prevents such degranulation. Depending on these 
results, the effects of VIP have been studied in the treatment 
of severe experimental hemoirhagic shock in combination 
with other therapeutic means used in this type of shock, such 
as naloxone, hypertonic saline infusion and/or blood reper- 
fusion, A combination of VIP and naloxone has yielded the 
best results on survival when it is used either alone or in con- 
junction with volume replacement after a severe hemorrhage. 
The important prospect of a combination of VIP and nalox- 
one is that it has apparently the most potent inhibitory effect 
on mast cell degranulation. In the light of the related exper- 
iments, we may conclude that the inhibition of mast cell 
degranulation has a beneficial effect on severe hemoirhagic 
shock; mast cell degranulation may thus be accepted as a 
physiopathological mechanisms contributing to the progres- 
sion of hemorrhagic shock state. 
INTRODUCTION 
• Hemorrhagic shock which is the most common 
type of shock encountered in clinical medicine, appears to 
be dependent on various conditions. Depending largely 
upon the amount of blood lost, it can progress into differ- 
ent stages from the compensated to the irreversible state. 
In the irreversible state, the shock progresses to a point 
which any therapeutic approach will be inadequate to save 
the life of the afflicted person. There has been much dis- 
cussion about what makes shock irreversible (1). It is 
known that a number of deleterious positive feedback 
mechanisms become operative; nevertheless, the key 
mechanisms associated with this stage have not been elu- 
dicated as yet (2,3). Therefore the question remains, What 
factor or factors lead to the eventual deterioration of 
microcirculation? Investigations have been focused to elu- 




a role in the disruption of microcirculation. With a better 
understanding of the physiopathologic mechanisms 
involved in irreversible shock, more and more patients can 
obviously be saved and treatment strategies may be 
improved. 
Production of eicosanoids, especialy of tromboxan A^ 
(4,5), the release of myocardial depresant factor from 
intestine (6), generation of free oxygen radicals (7,8), plug- 
ging of white blood cells and trombocytes in the capillary 
(2,9,10), swollen endothelial cells (11), activation of lyso- 
somal enzymes (12,13), and the waning of hyperglycemia 
(14) are claimed to be closely associated with the pro- 
gressive deterioration of microcirculatory homeostasis 
during hemorrhagic shock. 
After the discovery of endogenous opioid, as well as their 
receptors, a new insight has arisen as regards the mecha- 
nism of hemorrhagic shock (15,16). In 1978 Holaday and 
Faden proposed that endogenous opioids (endorphines) 
were major factors contributing to the physiopathology of 
shock (17). Experiments with opioid antagonists have 
revealed that endogenous opioid system within the central 
nervous system (CNS) are activated by stressful situations 
such as hemorrhagic shock (15,16,18). During hemor- 
rhagic shock plasma levels of endogenous opioids, espe- 
cially of p-endorphine, increase and contribute to the loss 
of circulatory homeostasis (15,19,20). In general, this may 
involve in an inhibition of sympathetic outflow, and per- 
haps an augmentation of parasympathetic tone 
(15,20,21,22). 
On the other hand, endogenous opiates have an another 
effect that could be partly responsible for the phys- 
iopathology observed in this form of shock, p- endorphine 
and various opiates or any stressful stimuli mediated by 
endogenous opiates cause mast cell degranulation and his- 
tamine release (23,24,25). Mast cell - derived histamine is 
believed to contribute to the disruption of cardiovascular 
function (15,20,26). During hemorrhage, therefore, mast 
cells can be activated by elevated p-endorphine and 
degranulated products of mast cells, among which hista- 
mine in particular, may be involved in the progress of hem- 
orrhagic shock to irreversible state (26,27). 
MAST CELLS 
• Granulated mast cells, the major source of the 
body's histamine, originate from the bone marrow. They 
are ordinarily distributed throughout the normal connec- 
tive tissue, where they are often situated adjacent to blood 
vessels and lymphatics, and beneath epithelial surfaces 






the skin (28). They are also localised in the CNS (29,30), 
sympathetic ganglia (31) and close to the intestinal pep- 
tidergic nerves (32). The function of mast cells which are 
close to the neurons is not yet clear. However, they possi- 
bly have modulatory effect on nerve activity (32,33). In 
addition, under physiological conditions a considerable 
amount of brain histamine is located in mast cells 
(30,33,34). Mast cells from different locations are shown 
to vary in their histochemical, ultrastructural, cytochemi- 
cal and functional properties. Depending on their het- 
erogeneity, they are categorized as mucosal and connec- 
tive tissue or typical and atypical mast cells (28,35). 
However, because of the insufficiency of the nomencla- 
ture in the recognition of the full extent of mast cell het- 
erogeneity, this type of classification has not yet been wide- 
ly accepted (36,37). 
Mast cell granules contain different kinds of substances 
such as histamine, heparin, slow reacting substance of ana- 
phylaxis (SRS-A), eozinophil chemotactic factor of ana- 
phylaxis (ECF-A), bradykinin, prostaglandins, leu- 
cotrienes, nitric-oxide-like factor, and vasoactive intesti- 
nal peptide (VlP).or closely related peptide (35,38- 
39,40,41). 
Histamine is known to be the major functional product of 
these cells. Mast cell-derived histamine has been impli- 
cated in the regulation of the immune system (42), mod- 
ulation of the synaptic transmission (31), tissue growth 
and repair (43); thus, it is not simply a vasoactive amine. 
Stimulation of mast cells cause degranulation and release 
of the granular products, especially histamine. Activated 
mast cells have some role in the regulation of various bio- 
logic responses and diseases (28). However, explanation 
of their specific roles in health and disease needs yet to be 
elucidated.  
Degranulation of mast cells may be included in response 
to a wide variety of substances other than IgE (44, 45). 
As mentioned above, one of the agents that cause mast 
cell degranulation is opioid peptides. There are numerous 
studies which confirm the capacity of these agents to cause 
mast cell degranulation (23,26,46,47,48). Therefore, mast 
cell degranulation during the hemorrhage is possibly the 
consequence of the elevated p-endorphines.  
THE EFFECT OF HEMORRHAGE ON MAST CELL 
DEGRANULATION 
• In our first study, we observed that hemorrhage 
caused mast cell degranulation in rats in correlation with 
the amount of blood loss (49). The most intense degranu- 
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lation was observed in the hypothalamus, especially in the 
nucleus arcuatus, and in the subcutaneous tissue. The gran- 
ules of the hypothalamic mast cells were found to be larg- 
er than those in other types of tissue. The number, hista- 
mine content and exocytosis of mast cells, on the other 
hand, were highest in the subcutaneous tissue. The inten- 
sity of degranulation gradually decreased in the peripher- 
al blood vessels, peritoneum and omentum, respectively. 
While there is a decreasing gradient in degranulation from 
subcutaneous tissue to the omentum, an increase in the 
number and histamine content of mast cells was found to 
be almost equal in two tissues, namely the peripheral blood 
vessels and the omentum. In this way, the hypothalamus 
and subcutaneous tissue could be accepted as indicator tis- 
sues for the determination of the intensity of degranula- 
tion. The most intense mast cell degranulation, i.e., that in 
the arcuate nucleus of hypothalamus, is possibly related to 
the (3-endorphine secreting neurons localized in this area 
(20). During stressful situations such as hemorrhage, (3- 
endorphine is released by these neurons either into the 
_ hypothalamus or into the blood stream, and binds opioid 
receptors on the surface of mast cells, thus causing degran- 
ulation and histamine release (20,26). In 1986 Nagy et al. 
observed a rapid, severalfold increase of plasma and tis- 
sue histamine on both conscious and anaesthetized dogs 
subjected to experimental hemorrhagic shock; they report- 
ed that the source of the elevated histamine was unknown 
(50). Correlating our results with Nagy's findings, we can 
conclude that degranulated mast cells might be the source 
of the histamine elevation during hemorrhage shock. 
THE SIGNIFICANCE OF MAST CELL 
DEGRANULATION DURING HEMORRHAGE 
• The question now arises, why do mast cells degran- 
ulate in hemorrhage? For the benefit? Or is this phe- 
nomenon to be considered as a harmful reaction? It is pos- 
sible that initially it is an essentially beneficial reaction, but 
that later on, when in excess, it becomes a deleterious phe- 
nomenon. 
Both, mast cell-derived histamine and p-endorphine, have 
been accepted as defensive mediators of the body to react 
to stressful stimuli (51,52), and the brain histamine turn 
over is increased by stress (28,52). Histamine is known to 
stimulate the release of ACTH (27,52). The amount of 
ACTH secretion is enhanced to meet the emergency situ- 
ation during stress and its release is mediated almost exclu- 
sively through the hypothalamus. Either i.c.v. administra- 
tion of histamine (53) or degranulation of brain mast cells 
by compound 48/80 (54) stimulates the pituitary-adreno- 
cortical activity. Therefore, mast cells located in the hypo- 
thalamus may serve as "emergency cells" when the body 
needs more histamine secretion. 
In addition to it is stimulatory efect on ACTH, histamine 
evokes an increase in plasma ADH level when adminis- 
tered peripherally or centrally (33,55). Therefore, a spec- 
ulative suggestion can be derived that even without a 
change in the osmolality of plasma, mast cell-derived his- 
tamine may be another responsible stimulator of ADH 
during hemorrhage. In hemorrhagic shock the beneficial 
effect of histamine elevation was implied by Nagy et al. 
(50). Subjecting animals to moderate hemorrhage, higher 
survival rates were observed in the groups displaying high- 
er plasma histamine levels and a higher ratio of histamine 
to norepinephrine and renin. As a powerful vasodilator 
agent, counterbalancing the excessive effect of vasocon- 
strictor agents, histamine could be a significant factor for 
survival (50,56). 
All the compensatory responses mentioned above which 
are initiated by histamine may turn out to be harmful to 
the body when histamine release or mast cell degranula- 
tion is excessive and/or prolonged. In a condition such as 
hemorrhage in which the intensity of mast cell degranula- 
tion gradually increases in correlation with the amount of 
blood loss, gradual histamine elevation and occurrence of 
the deleterious effect of histamine (57,58,59) must be 
expected. For this reason, when the insult is excessive, a 
modulatory mechanism may be expected to act to limit the 
degranulation involved. 
VASOACTIVE INTESTINAL PEPTIDE (VIP) AS A 
MODULATORY AGENT FOR MAST CELL 
DEGRAHULATIOH 
• Vasoactive intestinal peptide (VIP) is a basic pep- 
tide of 28 amino acid residues which was originally iden- 
tified in the gastrointestinal tract by Said and Mutt (60). 
Like various other peptides of the gastrointestinal or of 
endocrine origin, VIP is also present in the nervous sys- 
tem, its highest concentration (61,62,63) as well as that of 
histaminergic neurons (64,65) being found in the hypo- 
thalamus. VIP is also found in mast cells together with his- 
tamine, and from where it can be released by histamine 
releasers (40,41). A conclusion may now be drawn that 
VIP is to be found wherever histamine is present. It has 
been supposed that the VIP localized in mast cell has some 
modulatory effect on degranulation and mediator release 
from mast cells (40,41). VIP increases the intracellular c- 
AMP levels by activating adenylate cyclase (66,67). A 
decrease in c-AMP levels in mast cells stimulates the 
degranulation (36,38). Thus, possibly, inhibiting the release 
of mediators from mast cells through the increase in c- 
AMP mechanism, VIP may have an important modulat- 
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ing effect on the degranulation and Mstamine release. 
The inhibitory effect of VIP on mast cell degranulation 
was observed in our first experimental hemorrhagic shock 
model (49). In this experiment, the effects of VIP, H-[ and 
H2 receptor blockers and aprotinin on mast cell degranu- 
lation were investigated in rats exposed to hemorrhage. 
Degranulation was pevented by VIP in a dose dependent 
manner and 25 ng kg~l dose of VIP potentially inhibits the 
degranulation. On the other hand, Hj and H^ receptor 
blockers and aprotinin have no inhibitory effect. These 
data seem to support the suggestion that VIP has a mod- 
ulatory effect on histamine and other mediator release 
from mast cells. 
A relationship between VIP and histamine was observed 
in one of our earlier studies unrelated to hemorrhagic shock 
(25). In this experiment, exposure of guinea-pigs to stress 
(immobilization in cold for one hour and swimming there- 
after) caused degranulation and increased the number of 
mast cells in trachea. Contractile responses of isolated tra- 
cheal strips of stress-induced groups to both histamine and 
acetylcholine (Ach) were higher than the control. While 
the most relaxing effect of VIP occurred in the stress - 
induced strips precontracted by histamine, there was no 
relaxing effect of VIP to Ach contraction. These data were 
somewhat confirmatory to the suggestion about the mod- 
ulatory effect of VIP in the release of histamine and other 
mediators from pulmonary mast cells (41,69). Therefore, 
in any conditions that cause mast cell degranulation, VIP 
may exert its relaxant action on brochial smooth muscle 
by inhibiting histamine contractions.  
It is possible that these findings will lead to a new preven- 
tive and/or therapeutic application in hemorrhagic shock. 
Combination of VIP with the other therapeutic interven- 
tions used in the treatment of hemorrhagic shock may have 
a beneficial effect by modulating mast cell degranulation. 
In addition, VIP has a favourable effect also on cardio- 
vascular system via its systemic vasodilator and positive 
inotropic action (70,71). Therefore, either by modulating 
mast cell degranulation or through its cardiovascular 
effects, VIP seems to be a good candidate as a therapeu- 
tic agent in the treatment of hemorrhagic shock. 
VIP IN THE TREATMENT OF SEVERE 
EXPERIMENTAL HEMOR-RHAGIC SHOCK 
• Hemorrhagic shock treatment primarily consists 
of fluid replacement. However, restoration of blood vol- 
ume dose not always result in successful recovery. 
Microcirculatory disruption developing through various 
mechanisms may cause reduced reflow or no-reflow in the 
capillary bed even after systemic circulatory function was 
restored (2,3). Futhermore, restoration of flow to previ- 
ously ischemic tissues may trigger reperfusion injury which 
may result in increased tissue damage (8,72). For this rea- 
son, investigation has been focused to find the suitable 
agents that would be beneficial for microcirculation dur- 
ing hemorrhagic shock. Depending on the generation of 
free oxygen radicals involved here, some investigators stud- 
ied the prevention of oxygen-derived free radical injury in 
hemorrhagic shock (73,74). In these experiments, allop- 
urinol (a xanthine oxydase inhibitor) substantially 
increased the survival rate of dogs subjected to hemor- 
rhagic shock. Pentoxifylline is another agent used in the 
treatment of various kinds of shock including hemorrhag- 
ic shock (75). Waxman et al. have reported that pentoxi- 
fylline improves survival when used in addition to fluid 
replacement (76). Despite several questions remaining 
unanswered concerning pentoxifylline, it is claimed that it 
has significant hemorrheologic effects (77). Pentoxifylline 
decreases leukocyte (78,79) and trombocyte (80) aggre- 
gation, increases deformability of normal red cells (77), 
and improves the microcirculatory blood flow and tissue 
oxygenation (75,76). 
On the basis of increased endogenous opioids during hem- 
orrhagic shock, treatments were directed to block the effect 
of opiates. For this purpose, naloxone (81,82), TRH (83) 
and some antiserotoninergic agents were used (84). The 
most widely used agent has been naloxone (15,20,83). 
Being a synthetic broad spectrum opioid receptor antago- 
nist, naloxone competes with naturally occurring opioids 
and blocks their effects. With reference to the mechanism 
for the favourable action of naloxone in the treatment of 
hemorrhagic shock, emphasis has been placed on the 
observation that the drug increases sympathetic nerve 
activity (15,20,81,83), improves myocardial contractility 
(81,85,86), suppresses the release of lysosomal enzymes 
(12,13) and myocardial depresant factor (12,13), increase 
blood pressure (82,87,88,89) and cardiac out-put (82,90), 
improves the microcirculation and tissue metabolism 
(3,12), and leads to an increase in survival rates (12,15,88). 
However, and depending on some contraversial data, the 
effect of naloxone on both hemodynamics and the long- 
term survival of experimental animals exposed to severe 
hemorrhage is not significantly higher or even clear 
(91,92,93). 
Because the key mechanisms associated with irreversible 
hemorrhagic shock have not been elucidated sufficiently, 
and because there is insufficient improvement in the sur- 
vival with the use of naloxone alone, the prevention of mast 
cell degranulation by the administration of VIP, in addi- 
tion to the blockade of the opioid receptors by naloxone, 
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Mast cells degranulation in 40 % decrease of circulating blood volume: (a) Subcutaneous tissue (toluidine blue x 20 x 3.3), (b) Hypothalamus 
(toluidine blue x 40 x 3.3), and the prevention of that degranulation by a VIP and naloxone combination: (c) Subcutaneous tissue (toluidine blue x 
20 x 3.3), (d) Hypothalamus (toluidine blue x 40 x 3.3). 
may improve the survival rate in severe hemorrhagic shock. 
Accordingly, varying doses of VIP was combined with vary- 
ing doses of naloxone in our more recent study, and those 
combinations were used either alone or in conjunction with 
fluids in the treatment of severe hemorrhagic shock model 
in rats (94). In this experiment, a combination of 25 ng 
kg" 1 VIP + 5 mg kg"l naloxone showed the best results on 
survival when used alone after hemorrhage of the 40 per 
cent of the total blood volume. The importance of this com- 
bination is that it has apparently the most potent inhibito- 
ry effect on mast cell degranulation (Fig. 1 a,b,c,d). When 
this combination was given together with shed blood reper- 
fusion or 7.5% NaCl, survival rate increased relative to the 
adminisration of shed blood and of 7.5% NaCl alone. These 
findings suggest that inhibition of mast cell degranulation 
in addition to the volume replacement seems to be bene- 
ficial. Mast cell degranulation may thus be accepted as a 
physiopathological mechanism contributing to the pro- 
gression of the hemorrhagic shock state. In addition, it was 
observed in this experiment that blood reperfusion has no 
superiority over hypertonic saline treatment. This may be 
explained by the reperfusion injury which may develop dur- 
ing blood reperfusion (72,95). Recent evidence suggests 
that additional cellular injury can result during reperfusion 
of previously hypoxic tissue. The mechanisms of reperfu- 
sion injury are complex and hypothetically dependent on 
the formation of excess free oxygen radicals resulting from 
cellular calcium alteration, on the aggregation of trombo- 
cytes and leukocytes, and on trombus formation (9,72). 







Biomed Rev 2,1993 
  
  
hypertonic saline or blood showed some beneficial effect; 
this benefit may depend on the improvement of microcr- 
culation and the possible prevention of reperfusion side 
effects and of mast cell degranulation. 
Infusion of small volumes of hypertonic sodium chloride 
has recently been used for the treatment of hemorrhagic 
shock (96). An infusion of 7.5 per cent sodium chloride in 
a volume equal to, 10 per cent of shed blood in dogs suc- 
cessfuly restored normal circulatory function and indefi- 
nite survival time without accompanying blood transfu- 
sion; it was proposed that high plasma sodium is essential 
for survival (96,97). Depending on our and others' data, 
hypertonic saline supported by agents accepted as benefi- 
cial to microcirculation may be preferred to blood reper- 
fusion in the treatment of severe hemorrhagic shock. Such 
therapeutic modality avoids the adverse effects of blood 
transfusion, easier to find and less time-consuming. 
CONCLUSION 
• It appears that in the treatment of severe experi- 
mental hemorrhagic shock, volume replacement should be 
supported by the agents that have a salubrious effect on 
microcirculation. The number of such agents would appar- 
ently be increased by the elucidation of physiopathologic 
mechanisms involved in irreversible shock. Administration 
of these agents together with volume replacement seems 
to be essential for survival gain. Further experimental stud- 
ies are certainly needed to explain the overall mechanisms 
involved in the irreversible hemorrhagic shock with its fatal 
outcome. 
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